125 related articles for article (PubMed ID: 15100388)
1. Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein.
Woodahl EL; Yang Z; Bui T; Shen DD; Ho RJ
J Pharmacol Exp Ther; 2004 Sep; 310(3):1199-207. PubMed ID: 15100388
[TBL] [Abstract][Full Text] [Related]
2. MDR1 C2005T polymorphism changes substrate specificity.
Liu L; Fan L; Peng X; Hu D; Zhou H
Cancer Chemother Pharmacol; 2010 Aug; 66(3):617-23. PubMed ID: 20309692
[TBL] [Abstract][Full Text] [Related]
3. MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells.
Salama NN; Yang Z; Bui T; Ho RJ
J Pharm Sci; 2006 Oct; 95(10):2293-308. PubMed ID: 16883550
[TBL] [Abstract][Full Text] [Related]
4. Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells.
Hira A; Watanabe H; Maeda Y; Yokoo K; Sanematsu E; Fujii J; Sasaki J; Hamada A; Saito H
Biochem Pharmacol; 2008 Feb; 75(4):973-80. PubMed ID: 18054347
[TBL] [Abstract][Full Text] [Related]
5. MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells.
Woodahl EL; Yang Z; Bui T; Shen DD; Ho RJ
AIDS; 2005 Oct; 19(15):1617-25. PubMed ID: 16184031
[TBL] [Abstract][Full Text] [Related]
6. MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents.
Woodahl EL; Crouthamel MH; Bui T; Shen DD; Ho RJ
Cancer Chemother Pharmacol; 2009 Jun; 64(1):183-8. PubMed ID: 19123050
[TBL] [Abstract][Full Text] [Related]
7. Comparison of drug efflux transport kinetics in various blood-brain barrier models.
Bachmeier CJ; Trickler WJ; Miller DW
Drug Metab Dispos; 2006 Jun; 34(6):998-1003. PubMed ID: 16554372
[TBL] [Abstract][Full Text] [Related]
8. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells.
Mutoh K; Tsukahara S; Mitsuhashi J; Katayama K; Sugimoto Y
Cancer Sci; 2006 Nov; 97(11):1198-204. PubMed ID: 16925584
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance induced by ouabain via the stimulation of MDR1 gene expression in human carcinomatous pulmonary cells.
Brouillard F; Tondelier D; Edelman A; Baudouin-Legros M
Cancer Res; 2001 Feb; 61(4):1693-8. PubMed ID: 11245485
[TBL] [Abstract][Full Text] [Related]
10. The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells.
Traunecker HC; Stevens MC; Kerr DJ; Ferry DR
Br J Cancer; 1999 Nov; 81(6):942-51. PubMed ID: 10576649
[TBL] [Abstract][Full Text] [Related]
11. Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells.
Troost J; Lindenmaier H; Haefeli WE; Weiss J
Mol Pharmacol; 2004 Nov; 66(5):1332-9. PubMed ID: 15308763
[TBL] [Abstract][Full Text] [Related]
12. Interaction of imatinib mesilate with human P-glycoprotein.
Hamada A; Miyano H; Watanabe H; Saito H
J Pharmacol Exp Ther; 2003 Nov; 307(2):824-8. PubMed ID: 12975485
[TBL] [Abstract][Full Text] [Related]
13. A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells.
Crouthamel MH; Wu D; Yang Z; Ho RJ
J Pharm Sci; 2006 Dec; 95(12):2767-77. PubMed ID: 16917872
[TBL] [Abstract][Full Text] [Related]
14. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
15. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
16. Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells.
Acharya P; O'Connor MP; Polli JW; Ayrton A; Ellens H; Bentz J
Drug Metab Dispos; 2008 Feb; 36(2):452-60. PubMed ID: 17967933
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.
Hyafil F; Vergely C; Du Vignaud P; Grand-Perret T
Cancer Res; 1993 Oct; 53(19):4595-602. PubMed ID: 8402633
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity.
Sulová Z; Macejová D; Seres M; Sedlák J; Brtko J; Breier A
Toxicol In Vitro; 2008 Feb; 22(1):96-105. PubMed ID: 17920233
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential.
Alemán C; Annereau JP; Liang XJ; Cardarelli CO; Taylor B; Yin JJ; Aszalos A; Gottesman MM
Cancer Res; 2003 Jun; 63(12):3084-91. PubMed ID: 12810633
[TBL] [Abstract][Full Text] [Related]
20. Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A).
Heffeter P; Pongratz M; Steiner E; Chiba P; Jakupec MA; Elbling L; Marian B; Körner W; Sevelda F; Micksche M; Keppler BK; Berger W
J Pharmacol Exp Ther; 2005 Jan; 312(1):281-9. PubMed ID: 15331656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
